ROS1 with Interpretation by Immunohistochemistry with Reflex to FISH if Equivocal or Positive
Also known as: ROS1 IP
Use
The test is primarily used to determine the eligibility of patients with pulmonary adenocarcinomas for tyrosine kinase inhibitor therapy, specifically targeting the ROS1 fusion proteins and gene rearrangements. The detection of ROS1 rearrangements aids in identifying patients who may benefit from targeted tyrosine kinase inhibitor treatments such as crizotinib.
Special Instructions
Not provided.
Limitations
The test was developed and its performance characteristics determined by ARUP Laboratories and should be performed in a CLIA-certified laboratory. It is important to note that it has not been cleared or approved by the US FDA. The assay is limited to detecting ROS1 fusion proteins and ROS1 gene rearrangements without identifying specific partner genes in rearrangements. Positive results in IHC require confirmation by FISH.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 55229-9 - Immune stain study
- 94736-6 - Tissue block ID Spec
- 31208-2 - Specimen source
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
6 slides
Container
Tissue transport kit (ARUP supply #47808)
Collection Instructions
Collect formalin fixed paraffin embedded tissue. Transport tissue block or 6 unstained, positively charged slides.
Storage Instructions
Room temperature or refrigerated. Ship in cooled container during summer months.
Causes for Rejection
Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
| Refrigerated | Indefinitely |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant